Alnylam Pharmace. Stock

Description Alnylam Pharms

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company based in Cambridge, Massachusetts. The company was founded in 2002 and is primarily focused on the development of RNA interference (RNAi) therapies to treat rare genetic and cardio-metabolic diseases. Their products include ONPATTRO (patisiran), which is the first-ever RNAi therapeutic to be approved by the US Food and Drug Administration (FDA) for the treatment of hereditary transthyretin-mediated amyloidosis in adults. Alnylam also has a portfolio of other RNAi therapeutic candidates in clinical development for the treatment of various inherited diseases. As of May 2021, Alnylam Pharmaceuticals has a market capitalization of around $19 billion and its stock trades under the ticker symbol "ALNY" on the NASDAQ stock exchange.

Competitors of Alnylam Pharms

Alnylam Pharmaceuticals (ALNY) is a biopharmaceutical company that focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. Alnylam operates in a highly competitive industry, and its main competitors include:

1. Ionis Pharmaceuticals (IONS): Ionis is a biopharmaceutical company that focuses on the development of RNA-targeted therapeutics, including antisense technology. It competes with Alnylam in the RNAi drug development space.

2. Moderna Inc. (MRNA): Moderna is a biotech company that focuses on developing messenger RNA (mRNA) therapeutics and vaccines. Like Alnylam, Moderna is pioneering RNA-based therapies for diseases and conditions.

3. Biogen Inc. (BIIB): Biogen is a biotech company that develops and commercializes therapies for neurological diseases. While Biogen's focus is primarily on neurology, it does compete with Alnylam in the rare disease space.

4. Novartis (NVS): Novartis is a Swiss multinational pharmaceutical company that competes with Alnylam in the rare disease space. The company has several products in development for rare genetic diseases, including spinal muscular atrophy.

5. Regeneron Pharmaceuticals, Inc. (REGN): Regeneron is a biotech company that focuses on the development and commercialization of medicines for serious medical conditions. Like Alnylam, Regeneron has a particular focus on rare genetic diseases.

It is important to note that while these companies may be competitors to Alnylam, they may also collaborate with them on joint ventures or partnerships.

Suppliers of Alnylam Pharms

Alnylam Pharmaceuticals (ALNY) is a biopharmaceuticals company that focuses on developing RNA interference (RNAi) therapeutics for the treatment of various diseases. The company's suppliers have a critical role in supporting its research and development efforts, as well as the overall operations.

Alnylam Pharmaceuticals has several key suppliers in different areas, including:

1. Active pharmaceutical ingredients (API) suppliers: These are the companies that provide the raw materials used in the manufacturing of the company's RNAi therapeutics. Some of the main API suppliers for Alnylam Pharmaceuticals are DSM, Carbogen Amcis, and AMPAC Fine Chemicals.

2. Research and development suppliers: Alnylam Pharmaceuticals also partners with various suppliers to support its research and development activities. These suppliers typically provide specialized services or expertise in a particular area. Some of the key research and development suppliers for the company include Charles River Laboratories, Evotec, and Eurofins Scientific.

3. Clinical trial suppliers: To conduct clinical trials, Alnylam Pharmaceuticals partners with a range of suppliers, including contract research organizations (CROs), clinical trial management systems (CTMS), and central laboratory services. Some of the key clinical trial suppliers for the company include IQVIA, PPD, and Covance.

Overall, the suppliers of Alnylam Pharmaceuticals play a crucial role in supporting the company's operations and research and development efforts, and their contributions are vital to the company's success in developing RNAi therapeutics for the treatment of diseases.